"Ki-67 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
| Descriptor ID |
D019394
|
| MeSH Number(s) |
D12.776.660.625.500 D23.050.290.500 D23.101.140.400
|
| Concept/Terms |
Ki-67 Antigen- Ki-67 Antigen
- Antigen, Ki-67
- Ki 67 Antigen
- Antigen Ki-67
- Antigen Ki 67
- Ki-67, Antigen
- MIB-1 Antigen
- Antigen, MIB-1
- MIB 1 Antigen
- MIB-1 Protein
- MIB 1 Protein
- Antigen Ki67
- Ki67, Antigen
|
Below are MeSH descriptors whose meaning is more general than "Ki-67 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-67 Antigen".
This graph shows the total number of publications written about "Ki-67 Antigen" by people in this website by year, and whether "Ki-67 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma. Am J Surg Pathol. 2025 Feb 01; 49(2):130-137.
-
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors. Radiol Oncol. 2024 06 01; 58(2):196-205.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.
-
Overview of Ancillary Techniques in Cervical Cytology. Acta Cytol. 2023; 67(2):119-128.
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022 06; 33(6):658.
-
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819.
-
Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61.
-
Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas. Neuroradiology. 2019 Aug; 61(8):861-867.
-
Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients. Cancer Causes Control. 2019 Feb; 30(2):207-214.